2024 ESMO SARCOMA AND RARE CANCERS

Annual Congress

RESULTS FROM A PHASE 2 PART 1 TRIAL OF MECBOTAMAB VEDOTIN (BA3011), A CAB-AXL-ADC, IN PATIENTS WITH ADVANCED REFRACTORY SARCOMA

Seth M. Pollack, Anthony P. Conley, William Tap, Chueh-Chuan Yen, John Charlson, Lara E. Davis, Anna Chalmers, Mihaela Druta, Elizabeth T. Loggers, Jaspreet Grewal, Gerald Falchook, Brian Schulte, Thomas Yau, AeRang Kim, Herbert H. Loong, Suzanne George, Bhuvana Setty, Leo Mascarenhas, Gregory M. Cote, Breelyn Wilky

Presented by Seth M. Pollack





DECLARATION OF INTERESTS




Seth M. Pollack

Advisory and consulting fees from Adaptimmune, Bayer, Boehringer Ingelheim, Deciphera, Rain Therapeutics, and SpringWorks

SARCOMAS REMAIN DIFFICULT TO TREAT

Limited improvements in overall survival over time for metastatic soft tissue sarcomas¹



213

179

1997-2001

2002-2006

280

238

Few agents have efficacy in the treatment of osteosarcoma²

Selected Phase II Trials in Osteosarcoma²

Study	No. of Patients	Agent	Response	Years Study Open
A09713	10	Topotecan	No responses	1995–1998
ADVL0122	12	Imatinib	No responses	2002–2004
ADVL0421	13	Oxaliplatin	No responses	2004–2006
ADVL0524	11	Ixabepilone	No responses	2006–2007
CCG-0962	23	Docetaxel	1 PR, 1 CR, 2 NE, 19 with no response	1997–2001
EORTC phase II	15	Iproplatin	1 SD, 14 with no response	1997–1998
P9761	10	Irinotecan	9 with no response, 1 NE	1999–2005
P9963	16	Rebeccamycin	No responses	2000–2003
Phase II ridaforolimus	NR	Ridaforolimus	2 PR (total no. of patients NR)	2004–2005

 The historical use of radiographic response as the primary endpoint in osteosarcoma phase II trials has made it difficult to achieve PR²

1. Italiano A, Mathoulin-Pelissier S, Cesne AL, et al. Cancer. 2011;117(5):1049-1054. 2. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. J Clin Oncol. 2015;33(27):3029-3035.

150

147

115

106

87

80

Abbreviations: ADVL, Children's Oncology Group Developmental Therapeutic committee; CCG, Children's Cancer Group; CR, complete response; EORTC, European Organisation for the Research and Treatment of Cancer; NE, not evaluable; NR, not reported; PR, partial response; SD, stable disease

CONDITIONALLY ACTIVE BIOLOGIC (CAB) TECHNOLOGY

Selective and targeted to widen the therapeutic index



Acidic pH (5.8–6.7) at the cancer cell surface unveils binding sites that are shielded at normal pH (6.8 to >7.4)




CAB antibodies (BioAtla Inc.) bind only to these unveiled sites on cancer cells in the tumor microenvironment¹



Not masked or caged, thus differentiating CABs from prodrugs that require irreversible enzymatic cleavage





CABs have the potential for increased efficacy with improved safety relative to traditional antibodies



MECBOTAMAB VEDOTIN (BA3011): A CAB-AXL-ADC

AXL is expressed in a variety of tumor types, with overexpression associated with metastasis, tumor resistance to chemotherapy, and poor prognosis^{1,2}






1. Gay CM, Balaji K, Byers LA. Br J Cancer. 2017;116(4):415-423. 2. Zhang G, Wang M, Zhao H, Cui W. Oncol Lett. 2018;15(3):2726-2734.

Abbreviations: ADC, antibody-drug conjugate; AM, affinity matched; CAB, conditionally active biologic; DAR, drug antibody ratio; ELISA, enzyme linked immunosorbent assay; Ig, immunoglobulin; OD, optical density; VC-MMAE, valine-citrulline monomethylauristatin E.

CAB-AXL-ADC: PHASE 1 RESULTS


Durable responses observed among patients with UPS, LMS, and Ewing sarcoma; prospective, phase 2, single-arm UPS trial presently enrolling with data to be reported separately



PHASE 2 PART 1 OPEN-LABEL STUDY DESIGN

Inclusion criteria

- ≥12 years of age
- AXL-expressing[†] locally advanced, unresectable, or metastatic sarcoma
- Measurable disease by RECIST v1.1
- Received ≥1 regimen containing anthracycline and ≤3 prior lines of approved systemic therapy for histologic subtypes that typically receive chemotherapy[‡]



Endpoints

- DCR (objective response or stable disease for ≥12 weeks)
- Number of responders (complete or partial)
- PFS rate at week 12
- TEAEs

†Tumor membrane percent score ≥50%.

‡Prior chemotherapy was not required for histologic subtypes that do not typically receive chemotherapy.

*Tumor assessment by CT or MRI every 6 weeks from C1D1 until 12 weeks, then every 8 weeks up to 1 year, then every 12 weeks thereafter.


Abbreviations: C, cycle; CT, computed tomography; D, day; DCR, disease control rate; MRI, magnetic resonance imaging; PFS, progression-free survival; Q2W, every 2 weeks; RECIST, Response Evaluation Criteria in Solid Tumors; TEAE, treatment-emergent adverse event; v, version.

DEMOGRAPHICS AND BASELINE CHARACTERISTICS


	BA3011 monotherapy (n=87)	BA3011 + nivolumab (n=26)			
Age, y, mean (SD)					
Overall	51.5 (17.2)	55.3 (12.8)			
12—17	3 (3.4)	0			
18—65	65 (74.7)	21 (80.8)			
>65	19 (21.8)	5 (19.2)			
Gender, n (%)					
Male	44 (50.6)	6 (23.1)			
Female	43 (49.4)	20 (76.9)			
ECOG performance, n (%)					
0	38 (43.7)	12 (46.2)			
1	48 (55.2)	14 (53.8)			
Number of prior systemic therapies for metastatic disease, n (%)*					
1	19 (21.8)	5 (19.2)			
2	27 (31.0)	11 (42.3)			
3	23 (26.4)	7 (26.9)			
≥4	14 (16.1)	3 (11.5)			

*Four patients had missing data in the BA3011 monotherapy cohort. Data cutoff date: November 27, 2023. Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Sarcoma subtypes enrolled (excluding UPS)



BA3011 MONOTHERAPY ANTITUMOR ACTIVITY




- Disease control observed regardless of AXL expression
- Confirmed partial responses observed among osteosarcoma patients (n=2)

*DCR defined as objective response or stable disease for ≥12 weeks; 1 patient lost to follow-up was not efficacy-evaluable. Data cutoff date: November 27, 2023. Abbreviation: DCR. disease control rate.

OSTEOSARCOMA PHASE 2 PFS

BA3011 monotherapy




- Week 12 PFS of 45.5% exceeds COG threshold (40%) for establishing an "agent of interest" for additional development¹
- 2 out of 11 efficacy-evaluable patients with osteosarcoma achieved confirmed partial response

Lagmay JP, Krailo MD, Dang H, et al. J Clin Oncol. 2016;34(25):3031-3038.
Data cutoff date: November 27, 2023.
Abbreviations: COG, Children's Oncology Group; PFS, progression-free survival; W, week.

OSTEOSARCOMA RESPONSE TO BA3011 MONOTHERAPY

83-year-old man previously treated with liposomal doxorubicin and cabozantinib

Baseline chest CT with contrast (June 26, 2023)




Follow-up chest CT with contrast (August 14, 2023)

Data cutoff date: November 27, 2023. Abbreviation: CT, computed tomography.

LIPOSARCOMA AND SYNOVIAL SARCOMA PHASE 2 PFS

BA3011 monotherapy




Data cutoff date: November 27, 2023. Abbreviations: NE, not evaluable; PFS, progression-free survival; W, week.

SAFETY SUMMARY

Broadly well tolerated; most events low-grade and reversible

Most frequent TEAEs (≥15% of patients)



Summary of TEAEs

Characteristic, n (%)	BA3011 monotherapy (n=87)	BA3011 + nivolumab (n=26)	
Any TEAE	85 (97.7)	24 (92.3)	
Related TEAEs with CTCAE grade 3 or 4*	26 (29.9)	11 (42.3)	
Related serious TEAEs*	4 (4.6)	6 (23.1)	
Related TEAEs leading to death*	0	0	
Related TEAEs leading to treatment discontinuation*	7 (8.0)	1 (3.8)	

*As assessed by the investigator. Missing responses were counted as related

Related TEAEs of Special Interest

Characteristic, n (%)	BA3011 monotherapy (n=87)		BA3011 + nivolumab (n=26)	
	All grades	Grades 3–4	All grades	Grades 3–4
Peripheral neuropathy	27 (31.0)	0	7 (26.9)	0
Neutropenia	18 (20.7)	14 (16.1)	5 (19.2)	4 (15.4)
Abnormal liver function tests	14 (16.1)	3 (3.4)	3 (11.5)	1 (3.8)
Hyperglycemia	3 (3.4)	1 (1.1)	1 (3.8)	0

Data cutoff date: November 27, 2023.

Abbreviations: AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; TEAE, treatment-emergent adverse event.

CONCLUSIONS

- Every-other-week delivery of an AXL-targeted ADC, mecbotamab vedotin, attained disease control in 43% of patients with treatment-refractory sarcomas
- Treatment responses were observed among patients with osteosarcoma (2 PRs; week 12 PFS rate = 45.5%) and undifferentiated pleomorphic sarcoma (UPS; reported previously)¹
- Toxicity was manageable and few high-grade related TEAEs were observed
 - Very few related TEAEs led to treatment discontinuation
- Data observed thus far justifies further evaluation of mecbotamab vedotin, particularly among patients with osteosarcoma and UPS; a Phase 2 registrational study is ongoing (NCT03425279)

1. Wilky B, Druta M, Ahnert JR, et al. Poster presented at: Connective Tissue Oncology Society Annual Meeting; November 10-13, 2021. Abbreviations: ADC, antibody-drug conjugate; PFS, progression-free survival; PR, partial response; TEAE, treatment-emergent adverse event.

THANK YOU



ESMO SARCOMA AND RARE CANCERS

SARCOMAS REMAIN DIFFICULT TO TREAT

Limited improvements in overall survival over time for bone and soft tissue sarcomas¹

